Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tiaogan Lipi
- Development stage
- Unknown
- Lead developer
- Beijing Hospital of Traditional Chinese Medicine
- Administration
- Oral
01
Overview
Tiaogan Lipi is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Beijing Hospital of Traditional Chinese Medicine. It is primarily used as an adjuvant therapy for patients with primary liver cancer (hepatocellular carcinoma), particularly those undergoing transcatheter arterial chemoembolization (TACE). The formula is based on the TCM principle of "regulating the liver and strengthening the spleen" (Tiaogan Lipi), which aims to address the underlying systemic imbalances associated with liver disease. Clinical research, such as trial ChiCTR-IOR-16008036, evaluates its efficacy in preventing recurrence and improving the quality of life and liver function in post-TACE patients.
- Other names
- Tiaogan Lipi granuleTiaogan Lipi approach
Beyond the preview
Go deeper on Tiaogan Lipi.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tiaogan Lipi.